Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

Coave Therapeutics appoints Olivier Danos…

Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

NEW YORK, Sept. 30, 2021…

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Immunic and the University Medical…

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Coave Therapeutics and Théa Open…

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

ExeVir Announces First Patient Enrolled…

Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Cardior Raises €64 M Series…

ExeVir announces first subjects dosed in Phase I clinical study of potent COVID-19 neutralizing antibody

ExeVir announces first subjects dosed…

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Coave Therapeutics Closes €33 million…

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Immunic, Inc. Announces Closing of…

ExeVir and Mithra announce manufacturing collaboration for innovative Covid-19 treatments

ExeVir and Mithra announce manufacturing…